Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells

Blood

Volumn 115, Issue 25, 2010, Pages 5154-5163

  Voss, Ralf Holger ^a   Thomas, Simone ^a   Pfirschke, Christina ^b   Hauptrock, Beate ^a   Klobuch, Sebastian ^a   Kuball, Jürgen ^a,e   Grabowski, Margarete ^a   Engel, Renate ^a,f   Guillaume, Philippe ^c   Romero, Pedro ^d   Huber, Christoph ^a   Beckhove, Philipp ^b   Theobald, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d Hopital Orthopedique de la Suisse Romande   (Switzerland)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f European Institute for Research and Development of Transplantation Strategies   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DISULFIDE; GLYCOPROTEIN GP 100; PROTEIN KINASE; SIGNAL PEPTIDE; T LYMPHOCYTE RECEPTOR; TYROSINE; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN P53; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; BETA CHAIN; CELL MEMBRANE; CYTOTOXICITY; EFFECTOR CELL; HEMATOLOGIC MALIGNANCY; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; MELANOMA; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SAFETY; T LYMPHOCYTE; TUMOR; TUMOR GROWTH; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PROTEIN TERTIARY STRUCTURE; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HUMANS; IMMUNITY, CELLULAR; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954663154     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-254078     Document Type: Article

References (50)

1. Theobald M, Biggs J, Hernandez J, et al. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med. 1997;185(5):833-841. (Pubitemid 27119867)
2. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-129.
3. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3):535-546.
4. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A. 1995;92(26):11993-11997. (Pubitemid 26013997)
5. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323-5337.
6. Kuball J, Schmitz FW, Voss RH, et al. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity. 2005;22(1):117-129. (Pubitemid 40143456)
7. Schaft N, Willemsen RA, de Vries J, et al. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol. 2003;170(4):2186-2194. (Pubitemid 36197443)
8. Weinhold M, Sommermeyer D, Uckert W, Blankenstein T. Dual T cell receptor expressing CD8+ T cells with tumor- and self-specificity can inhibit tumor growth without causing severe autoimmunity. J Immunol. 2007;179(8):5534-5542.
9. van Loenen MM, Hagedoorn RS, Kester MG, et al. Kinetic preservation of dual specificity of coprogrammed minor histocompatibility antigen-reactive virus-specific T cells. Cancer Res. 2009;69(5):2034-2041.
10. Heemskerk MH, Hagedoorn RS, van der Hoorn MA, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 2007;109(1):235-243.
11. Voss RH, Willemsen RA, Kuball J, et al. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol. 2008;180(1):391-401.
12. van der Veken LT, Coccoris M, Swart E, et al. Alpha beta T cell receptor transfer to gamma delta T cells generates functional effector cells without mixed TCR dimers in vivo. J Immunol. 2009;182(1):164-170.
13. Chung S, Wucherpfennig KW, Friedman SM, Hafler DA, Strominger JL. Functional three-domain single-chain T-cell receptors. Proc Natl Acad Sci U S A. 1994;91(26):12654-12658.
14. Zhang T, He X, Tsang TC, Harris DT. Transgenic TCR expression: comparison of single chain with full-length receptor constructs for T-cell function. Cancer Gene Ther. 2004;11(7):487-496. (Pubitemid 38902675)
15. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2- derived tumor antigen by TCR gene transfer. Nat Immunol. 2001;2(10):962-970. (Pubitemid 32976170)
16. Robert B, Guillaume P, Luescher I, Romero P, Mach JP. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol. 2000;30(11):3165-3170.
17. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994;179(3):1005-1009. (Pubitemid 24979056)
18. Voss RH, Kuball J, Theobald M. Designing TCR for cancer immunotherapy. Methods Mol Med. 2005;109:229-256.
19. Schaft N, Dorrie J, Muller I, et al. A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother. 2006;55(9):1132-1141. (Pubitemid 43800728)
20. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451(7176):345-349.
21. Robinson CR, Sauer RT. Optimizing the stability of single-chain proteins by linker length and composition mutagenesis. Proc Natl Acad Sci U S A. 1998;95(11):5929-5934.
22. Zhou M, Yeager AM, Smith SD, Findley HW. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood. 1995;85(6):1608-1614.
23. Willemsen RA, Weijtens ME, Ronteltap C, et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther. 2000;7(16):1369-1377. (Pubitemid 30662242)
24. Bialer G, Horovitz-Fried M, Ya'acobi S, Morgan RA, Cohen CJ. Selected murine residues endow human TCR with enhanced tumor recognition. J Immunol. 2010;184(11):6232-6241.
25. Voss RH, Kuball J, Engel R, et al. Redirection of T cells by delivering a transgenic mouse- derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression. Immunol Res. 2006;34(1):67-87. (Pubitemid 43780377)
26. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood. 2007;109(6):2331-2338. (Pubitemid 46425872)
27. Lefranc MP, Pommie C, Kaas Q, et al. IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains. Dev Comp Immunol. 2005;29(3):185-203. (Pubitemid 39575119)
28. Di Bartolo V, Mege D, Germain V, et al. Tyrosine 319, a newly identified phosphorylation site of ZAP-70, plays a critical role in T cell antigen receptor signaling. J Biol Chem. 1999;274(10):6285-6294. (Pubitemid 29111040)
29. Williams BL, Irvin BJ, Sutor SL, et al. Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-gamma1 and Ras activation. EMBO J. 1999;18(7):1832-1844.
30. Beckhove P, Schutz F, Diel IJ, et al. Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer. 2003;105(4):444-453. (Pubitemid 36578546)
31. Romero P, Zippelius A, Kurth I, et al. Four functionally distinct populations of human effectormemory CD8+ T lymphocytes. J Immunol. 2007;178(7):4112-4119. (Pubitemid 46492360)
32. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294-305.
33. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6(5):383-393.
34. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol. 2002;2(7):512-519.
35. Richman SA, Aggen DH, Dossett ML, et al. Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments. Mol Immunol. 2009;46(5):902-916.
36. Call ME, Pyrdol J, Wiedmann M, Wucherpfennig KW. The organizing principle in the formation of the T cell receptor-CD3 complex. Cell. 2002;111(7):967-979. (Pubitemid 36044689)
37. Kuhns MS, Davis MM. Disruption of extracellular interactions impairs T cell receptor- CD3 complex stability and signaling. Immunity. 2007;26(3):357-369.
38. Kersh EN, Kersh GJ, Allen PM. Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med. 1999;190(11):1627-1636.
39. Haks MC, Cordaro TA, van den Brakel JH, et al. A redundant role of the CD3 gamma- immunoreceptor tyrosine-based activation motif in mature T cell function. J Immunol. 2001;166(4):2576-2588.
40. Recio MJ, Moreno-Pelayo MA, Kilic SS, et al. Differential biological role of CD3 chains revealed by human immunodeficiencies. J Immunol. 2007;178(4):2556-2564.
41. Yokosuka T, Kobayashi W, Sakata-Sogawa K, et al. Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation. Immunity. 2008;29(4):589-601.
42. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol. 2002;20(1):70-75. (Pubitemid 34044918)
43. Mallaun M, Naeher D, Daniels MA, et al. The T cell receptor's alpha-chain connecting peptide motif promotes close approximation of the CD8 coreceptor allowing efficient signal initiation. J Immunol. 2008;180(12):8211-8221.
44. Sommermeyer D, Uckert W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol. 2010;184(11):6223-6231.
45. Boulter JM, Glick M, Todorov PT, et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 2003;16(9):707-711. (Pubitemid 37314399)
46. Szymczak AL, Workman CJ, Wang Y, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol. 2004;22(5):589-594.
47. Labrecque N, Whitfield LS, Obst R, et al. How much TCR does a T cell need? Immunity. 2001;15(1):71-82. (Pubitemid 32728321)
48. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 2001;7(4):452-458. (Pubitemid 32298548)
49. Xue SA, Gao L, Thomas S, et al. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica. 2010;95(1):126-134.
50. Nervi B, Rettig MP, Ritchey JK, et al. Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp Hematol. 2007;35(12):1823-1838. (Pubitemid 350117108)